An observational study in Pain Management and Autism Spectrum Disorder (ASD), sponsored by Groupe Hospitalier Mutualiste de Grenoble. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Groupe Hospitalier Mutualiste de Grenoble · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies in Autism Spectrum Disorder with a site in France — 51 open to participants now, 55 under way, 2 of them phase 3. Autism Spectrum Disorder · France.
Among the 110 studies in Autism Spectrum Disorder with a site in France, this one is the 20th largest by planned enrollment of the 33 observational ones that give a count, is one of 15 that started in 2026, is one of 33 observational ones, reaches primary completion later than 30 of the 54 other live ones, and was the 103rd registered.
1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.
Browse Autism Spectrum Disorder studies →51 of the 110 studies in Autism Spectrum Disorder with a site in France are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in France, United States, Germany and 7 more countries
Ages 5–17
Hopital La Musse · Sites in France
Ages 15–17 · Healthy volunteers
Hospices Civils de Lyon · Sites in France
Ages 5–50
Fondation FondaMental · Sites in France
Ages 15–60 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 8–16
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 12 · Phase 3 9
First in 2007; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 103 across 323 observational studies indexed under Autism Spectrum Disorder.
Median enrollment 70 across the 77 interventional studies, 120 across the 33 observational. Of the 43 that completed or were terminated, 8 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 110 have an industry lead sponsor. The 10 most frequent:
Groupe Hospitalier Mutualiste de Grenoble is the lead sponsor of 12 studies on the registry; 4 are open to participants now.
Groupe Hospitalier Mutualiste de Grenoble has 1 study filed under Autism Spectrum Disorder — fewer than ten, so there is no comparison to draw.
17 of the studies in Autism Spectrum Disorder with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07655115Phase 3Hospital General Universitario Gregorio MarañonSingle Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th | 2026-12-31 |
| NCT06871696Institut National de la Santé Et de la Recherche Médicale, FranceGenetic of Intellectual Deficiency and Autism Spectrum Disorders (RaDiCo-GenIDA) | 2026-11 |
| NCT05512637University Hospital, MontpellierScreening for Neurodevelopmental Disorders in Siblings of Children With Autism Diagnosed in Tertiary Centers | 2026-11 |
| NCT04638452Centre Hospitalier Charles Perrens, BordeauxEvaluation of Behavioural Psycho & Physiological Responses in People With ASD During a Blood Test in Routine Care Practice | 2026-11-30 |
| NCT05864508University Hospital, ToulouseInterest of Oxytocin as an Adjuvant Treatment of Psycho-educational Measures in Challenging Behaviors in Children With Autism Spectrum Disorders and Moderate to Severe Intellectual Disability: Feasibility and Safety Study. | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 110 studies in Autism Spectrum Disorder with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Autism is a neurodevelopmental disorder (NDD) characterized by two key features: persistent deficits in communication and social interaction, and restricted, repetitive patterns of behavior, interests, and activities. Ninety-five percent of children aged 3 to 6 with autism spectrum disorder (ASD) have sensory peculiarities. In adulthood, this figure remains at 90%. This atypical sensory processing has been part of the DSM diagnostic criteria since 2013.
Each sense can be affected by hypo- or hypersensitivity. In the continuum of this particular sensory processing, pain, which is defined as an unpleasant sensory and emotional experience, can be very present but also difficult to detect and manage. It is now established that there are other characteristics that impact pain in ASD: information processing time may be longer, referred to as "latency time," but there are also difficulties in representing the body schema and difficulties in identifying and/or interpreting perceptions. Expression may be atypical, and there may be an apparent lack of reaction to pain due to a lack of flexibility.
All of these characteristics themselves vary over time (with age, the menstrual cycle, lack of sleep, fatigue, etc.), to the point that even pain specialists in pain clinics may not recognize them.
It is therefore essential to carry out appropriate, individualized assessments.
The scientific literature refers to the high frequency of painful events in ASD. For example, the prevalence of gastrointestinal disorders with their associated abdominal pain is significantly higher. Recent research has revealed that 82.4% of children and adolescents with ASD have at least one gastrointestinal symptom. Researchers have found that children with ASD are almost eight times more likely to have one or more chronic gastrointestinal symptoms than typically developing children. There are also more common comorbidities that facilitate or maintain chronic pain: Ehler Danlos syndrome and hypermobility spectrum disorders, IBD, ADHD, post-traumatic stress disorder, depression, migraines and tension headaches, anxiety disorders, epilepsy, small fiber pathologies, nutritional deficiencies, musculoskeletal disorders, etc.
Mutations in certain genes involved in ASD (such as SCN9A, SHANK3, and CNTNAP2) lead to impaired neuronal function, producing different responses to pain, as demonstrated in both mouse and human models. The links between ASD and chronic pain are therefore complex. Sometimes it is the unusual characteristics of the pain that could lead to a diagnosis of ASD.
The concept of central sensitization (CS), which underlies the type of pain known as "nociplastic," helps explain the state of pain hypersensitivity and pathologies such as fibromyalgia and irritable bowel syndrome. In 2022, Grant et al. found that 21% of adults with ASD surveyed in the cohort reported having a diagnosis of central sensitization syndrome (CSS), but 60% scored at or above the cut-off. This suggests that CS symptoms such as pain and fatigue are very common in people with autism, and perhaps more prevalent than in the general population. For example, three-quarters of women diagnosed with ASD and/or ADHD in childhood report chronic pain in adulthood.
The issue is the disability associated with this chronic pain and the impairment of quality of life.
Autism is a neurodevelopmental disorder (NDD) characterized by two key features: persistent deficits in communication and social interaction, and restricted, repetitive behaviors, interests, and activities.
95% of children aged 3 to 6 with autism spectrum disorder (ASD) have sensory peculiarities. In adulthood, this figure is estimated to be 90%..
This atypical sensory perception has been included in the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM) since 2013, and recommendations advocate for sensory assessment (HAS, 2010) as part of treatment.
Each sense can be affected by hypo- or hypersensitivity. Pain is now defined by international consensus as an unpleasant sensory and emotional experience, which may or may not be associated with injury. In the continuum of this particular sensory experience, pain can be very present but also difficult to detect and manage.
It is now established that there are other characteristics that impact pain in ASD: information processing time may be longer, referred to as "latency time," but there are also difficulties in representing body image and difficulties in identifying and/or interpreting perceptions. The expression of pain may be atypical, with an apparent lack of reaction to pain due to a lack of flexibility. All of these characteristics themselves vary over time, with age, the menstrual cycle, lack of sleep, fatigue, etc., to the point that even pain specialists in pain clinics may not recognize it. It is therefore essential to carry out appropriate and individualized assessments.
The scientific literature refers to the high frequency of painful events in ASD. For example, the prevalence of gastrointestinal disorders with associated abdominal pain is significantly higher. Recent research has revealed that 82.4% of children and adolescents with ASD have at least one gastrointestinal symptom. Researchers have found that children with ASD are almost eight times more likely to have one or more chronic gastrointestinal symptoms than typically developing children.
In addition, there are more common comorbidities that facilitate or maintain chronic pain : Ehler Danlos syndrome and hypermobility spectrum disorders, IBD, ADHD, post-traumatic stress disorder, depression, migraines and tension headaches, anxiety disorders, epilepsy, small fiber pathologies, nutritional deficiencies, and musculoskeletal disorders.
Mutations in certain genes involved in ASD (such as SCN9A, SHANK3, and CNTNAP2) lead to impaired neuronal function, producing different responses to pain, as demonstrated in both mouse and human models. The links between ASD and chronic pain are therefore complex. In some cases, it is the unusual characteristics of the pain that can lead to a diagnosis of ASD.
Pain can be nociceptive (due to lesions that stimulate peripheral receptors) or neuropathic (related to a lesion or pathology of the nervous system). A third mechanism of pain is now being discussed, linked to the plasticity of the nervous system, known as nociplastic pain.
The concept of central sensitization (CS) underlying this type of pain helps explain the state of painful hypersensitivity and conditions such as fibromyalgia and irritable bowel syndrome. There are close links between these conditions and ASD.
Grant et al. in 2022 found that 21% of adults with ASD surveyed in the cohort reported having a diagnosis related to central sensitization syndrome (CSS), but 60% scored 40 or higher, the cut-off point for the Central Sensitization Index, which rates symptoms of CS. These signs of CS are therefore thought to be common and may explain why the prevalence of chronic pain (lasting more than three months) is high in ASD. This suggests that CS symptoms such as pain and fatigue are very common in people with autism and may be more prevalent than in the general population.
In comparison, the prevalence of chronic pain in France is estimated at 31.7%. According to Grant et al., autistic women are more likely to report a diagnosis of CFS and exhibit more symptoms of CF than men. Sensory sensitivity, anxiety, age, and gender were significant predictors of CF symptoms, with sensory sensitivity and anxiety modulating the relationship between autistic traits and CF symptoms. Three-quarters of women diagnosed with ASD and/or ADHD in childhood report chronic pain in adulthood. The issue is the disability associated with this chronic pain and the impairment of quality of life.
There is no specific tool for assessing nociplastic pain. The Central Sensitization Inventory (CSI) is a self-report questionnaire validated in 2014 by Neblett et al. that attempts to measure central sensitization. The cut-off point was set at 40.
In the study by Grant et al., which surveyed adults with ASD without TDI using this tool, the group with SSC had an average score of 55.3 (versus 52.4 in Neblett's cohort), but the group without diagnosed SSC had a score of 40.6 (versus 30.9 in Neblett's cohort). This suggests that pain and fatigue are very common in people on the autism spectrum. They could explain why the prevalence of chronic pain (i.e., lasting more than 3 months) is high in ASD and why the nociplastic nature of this pain must be taken into account.
On the other hand, there is a FIRST self-administered questionnaire for fibromyalgia that allows for simple screening for this condition, which is at the top of the list of CSDs. Finally, as Grant et al. Investigator investigate the relationship between autistic traits and central sensitization syndromes by studying the correlation with the 10-item Autism Spectrum Quotient (AQ) and the relationship between sensory perception and central sensitization syndromes by studying the correlation with the Sensory Perception Quotient (SPQ) and SSC.
Chronic pain is common in ASD, and its nociplastic nature is poorly understood. In this context, the objective of this study is to determine the prevalence of signs of central sensitization in adults with ASD (without intellectual developmental disorder).
patient aged 18 or older who has been diagnosed with an autism spectrum disorder without an intellectual disability,
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participation in this study includes an interview with the research staff (1 hour). During this appointment, they will check the eligibility criteria for the study and collect initial study data (gender, age) and then data on your medical history (date of ASD diagnosis, mental/physical history/comorbidities). You will then be asked to complete the following questionnaires (taking 20 minutes): * SCI questionnaire, assessing central sensitization * HAD questionnaire, assessing anxiety and depression * Autism Spectrum Quotient, assessing autism symptoms * Sensory Perception Quotient * FIRST questionnaire, assessing symptoms and pain related to fibromyalgia * ASRS questionnaire, assessing attention disorders * Numerical pain scale * Numerical well-being perception scale * Numerical physical health perception scale
Determine the prevalence of signs of central sensitization in adults on the autism spectrum without intellectual developmental disorders.
Percentage of patients with a CSI score ≥ 40 Total Score CSI :\[0-100\] A CSI score \> 40 points defines clinically significant central sensitization. The score is divided into intervals: 0 to 29 = subclinical CS, 30 to 39 = mild CS, 40 to 49 = moderate CS, 50 to 59 = severe CS, 60 to 100 = extreme CS.
Time frame: At inclusion
Determine the average level of central sensitivity in adults on the autism spectrum, with at least one diagnosis of SSC
Average CSI score (part A) in this subgroup Total Score CSI (part A): \[0-100\] The score is divided into intervals: 0-29 = subclinical central sensitisation, 30-39 = mild central sensitisation, 40-49 = moderate central sensitisation, 50-59 = severe central sensitisation, 60-100 = extreme central sensitisation.
Time frame: At inclusion
Determine the average level of central sensitivity in adults on the autism spectrum without a diagnosis of SSC
Average CSI score (part A) in this subgroup Total Score CSI (part A) :\[0-100\] The score is divided into intervals: 0-29 = subclinical central sensitisation, 30-39 = mild central sensitisation, 40-49 = moderate central sensitisation, 50-59 = severe central sensitisation, 60-100 = extreme central sensitisation.
Time frame: At inclusion
Determine the prevalence of SSC diagnoses
Percentage of patients with at least one SC diagnosis (part B of the CSI) Total Score SCI (part B) : \[0-10\].This section provides additional clinical information, but does not count toward the numerical score.
Time frame: At inclusion
Determine the average anxiety level
Average HAD-A Anxiety Score Total Score HAD-A : \[0-21\] Score \[0 - 7\]: no anxiety and/or depressive disorders. Score \[8- 10\]: questionable symptoms. Score \[11 - 21: confirmed anxiety and/or depressive disorders of varying severity.
Time frame: At inclusion
Determine the average level of depression
Average HAD-D Depression Score Total Score HAD-D : \[0-21\] Score \[0 - 7\]: no anxiety and/or depressive disorders. Score \[8- 10\]: questionable symptoms. Score \[11 - 21: confirmed anxiety and/or depressive disorders of varying severity.
Time frame: At inclusion
Determine the prevalence of subjects who test positive on the fibromyalgia self-assessment questionnaire
Percentage of patients with a score greater than 5 on the FIRST self-assessment questionnaire Total Score FIRST :\[0-6\] A score of 5 out of 6 items can detect fibromyalgia with a sensitivity of 90.5% and a specificity of 85.7%.
Time frame: At inclusion
Determine the prevalence of acute pain in the last 12 weeks
Percentage of subjects with pain score \>3 for several days in the last 12 weeks Total score EN Pain : \[0-10\] (0 very bad to 10 very good)
Time frame: over the last 12 weeks prior to inclusion
Determine the average level of chronic pain
Average EN pain over the last 24 hours and over the last 7 days Total score EN Pain : \[0-10\] (0 very bad to 10 very good)
Time frame: T1 : over the last 24 hours prior to inclusion T2 : over the last 7 days prior to inclusion
Determine the prevalence of chronic pain
Percentage of subjects with pain score \>3, every day or almost every day for at least 3 months Total score EN Pain : \[0-10\] (0 very bad to 10 very good)
Time frame: over the last 3 months prior to inclusion
To investigate the relationship between the CSI score and several aspects of quality of life and autism symptoms.
Logistic regression model incorporating the following explanatory variable: \- Sensory Perception Quotient (SPQ) ; Total Score SPQ : \[0-105\] a lower score indicates higher sensory sensitivity
Time frame: At inclusion
To investigate the relationship between the CSI score and several aspects of quality of life and autism symptoms.
Logistic regression model incorporating the following explanatory variable: \- EN pain; Total Score EN Pain : \[0-10\] (0 very bad to 10 very good)
Time frame: At inclusion
To investigate the relationship between the CSI score and several aspects of quality of life and autism symptoms.
Logistic regression model incorporating the following explanatory variable: \- HAD-A Anxiety Score; Total HAD-A score: \[0-21\], Score \[0-7\]: no anxiety and/or depressive symptoms. Score \[8-10\]: borderline symptoms. Score \[11-21\]: confirmed anxiety and/or depressive symptoms of varying severity.
Time frame: At inclusion
To investigate the relationship between the CSI score and several aspects of quality of life and autism symptoms.
Logistic regression model incorporating the following explanatory variable: \- HAD-D Depression Score; Total Score HAD-D : \[0-21\], Score \[0-7\]: no anxiety and/or depressive symptoms. Score \[8-10\]: borderline symptoms. Score \[11-21\]: confirmed anxiety and/or depressive symptoms of varying severity.
Time frame: At inclusion
To investigate the relationship between the CSI score and several aspects of quality of life and autism symptoms.
Logistic regression model incorporating the following explanatory variable: \- Adult Self-Report Scale Symptom (ASRS) ; Total Score ASRS1.1 \[0-24\], A score of 14 or higher indicates a positive result on the ADHD screening test. The total score can be classified into four categories: 0-9 = mildly negative; 10-13 = strongly negative; 14-17 = mildly positive; and 18-24 = strongly positive
Time frame: At inclusion
To investigate the relationship between the CSI score and several aspects of quality of life and autism symptoms.
Logistic regression model incorporating the following explanatory variable: \- EN "good physical health" ; Total Score EN "good physical health" : \[0-10\] (0 very bad to 10 very good)
Time frame: At inclusion
To investigate the relationship between the CSI score and several aspects of quality of life and autism symptoms.
Logistic regression model incorporating the following explanatory variable: \- EN "well-being"; Total Score EN "well-being"; : \[0-10\] (0 very bad to 10 very good)
Time frame: At inclusion
To investigate the relationship between the CSI score and several aspects of quality of life and autism symptoms.
Logistic regression model incorporating the following explanatory variable: \- Autism Quotient (AQ) ; Total Score AQ :\[0-50\] , The average score for neurotypical individuals is 19 for women and 21.5 for men; The higher the score, the more autistic traits are present; People with Asperger's syndrome or another autism spectrum disorder score an average of 35.2; A score above 32 indicates the clinical threshold for Asperger's syndrome.
Time frame: At inclusion
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Jul 2027, 17 months after the start.
Of 98 non-industry observational studies under Autism Spectrum Disorder, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 120. This study's planned 17 months is below that.
Counting every sponsor, half of 112 studies reached it within 40 months; a quarter within 26 and three quarters within 120.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Groupe Hospitalier Mutualiste de Grenoble